Humana price target maintained at $283 by RBC on long-term growth view

RBC Capital reiterated its Outperform rating and $283 price target on Humana (HUM) following the company's investor conference, citing confidence in long-term EPS growth despite near-term headwinds from Stars ratings. Humana is prioritizing long-term earnings, projecting $38-42 EPS by 2028, while navigating anticipated Stars-related earnings volatility in 2026-2027. Other analysts have mixed views, with UBS maintaining a neutral rating, Truist adjusting its price target to $280 with a hold rating, Mizuho reiterating an outperform rating with a $316 price target, and Cantor Fitzgerald maintaining a neutral rating with a $290 price target, reflecting varied perspectives on Humana's strategies and market dynamics.

Analysis

RBC Capital has reaffirmed its Outperform rating and $283.00 price target for Humana (NYSE:HUM), signaling confidence in the company's long-term earnings growth strategy despite anticipated near-term challenges, particularly from Stars rating headwinds. Humana, currently trading at $243.08 with a market capitalization of $29.35B, is prioritizing sustained earnings growth over immediate margin recovery. Management commentary suggests a potential 2028 earnings per share (EPS) range of approximately $38-42, including Stars bonus payments, a figure echoed by Humana's own Investor Day projection of $36-44 EPS by 2028. This outlook is supported by strategies focusing on Individual Medicare Advantage, other business lines, and enterprise operating efficiencies. The company exhibits a solid financial base, evidenced by 10.09% revenue growth, a P/E ratio of 17.19, a 'GREAT' overall health score, and a consistent dividend yielding 1.5%. Despite an expected uneven earnings trajectory in 2026 and 2027 due to Stars headwinds, Humana anticipates its Medicare Advantage margins, excluding Stars impacts, will improve through 2028. Analyst sentiment is mixed: while RBC and Mizuho (Outperform, $316 PT) are optimistic, UBS (Neutral) and Truist Securities (Hold, $280 PT) express more caution, citing unresolved questions. Cantor Fitzgerald (Neutral, $290 PT) noted the positive, albeit anticipated, exclusion of potential Medicare Advantage cuts from current legislative considerations, which reduces some uncertainty. The InvestingPro Fair Value analysis also suggests Humana's stock is currently undervalued.

Key Decisions for Investors

• Investors should consider Humana's long-term EPS growth potential, projected to be between $36 and $44 by 2028, against the backdrop of expected earnings volatility in 2026-2027 due to Stars rating headwinds.
• Monitor the company's ability to improve Medicare Advantage margins (excluding Stars impact) through 2028 and navigate the upcoming Stars challenges as key performance indicators.
• Given the mixed analyst ratings and the stock's current valuation, which InvestingPro suggests is undervalued, investors should conduct thorough due diligence, weighing the potential for long-term appreciation against near-term uncertainties.
• Assess the implications of the exclusion of Medicare Advantage cuts from legislative considerations, as this alleviates a key risk factor for Humana's revenue prospects.